EXEL - Exelixis, Inc.
| Previous Close | 20.93 |
| Open | 21.06 |
| Bid | 21.42 x 1300 |
| Ask | 21.46 x 800 |
| Day's Range | 21.01 - 21.51 |
| 52 Week Range | 18.03 - 32.50 |
| Volume | 554,924 |
| Avg. Volume | 3,777,737 |
| Market Cap | 6.35B |
| Beta | 2.23 |
| PE Ratio (TTM) | 43.39 |
| EPS (TTM) | 0.49 |
| Earnings Date | Jul 31, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.00 |
- ACCESSWIRE•yesterday
Wired News – EU Approved Exelixis/Ipsen’s CABOMETYX in Europe for Intermediate - or Poor-Risk Advanced Renal Cell Carcinoma
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want access to our free research report on Exelixis, Inc. (NASDAQ: EXEL), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EXEL as the Company's latest news hit the wire. On May 17, 2018, the Company announced that the European Commission (EC) has approved the Company's partner Ipsen for CABOMETYX® (cabozantinib) 20 mg, 40 mg, and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (RCC) in the European Union.
- Motley Fool•3 days ago
3 Top Biotech Stocks to Buy Right Now
Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.
- Market Realist•4 days ago
Exelixis Is Focused on Management of the Cabozantinib Franchise
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
- Market Realist•4 days ago
Label Expansion May Boost Cabometyx’s Revenue in 2018
On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.
Market Realist•4 days agoCabometyx Is Expected to Witness a Robust Revenue Rise in 2018
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.
- Market Realist•5 days ago
Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.
Market Realist•5 days agoExelixis Is Expected to Report a Robust Revenue Rise in 2018
The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.
- Zacks•5 days ago
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Market Realist•5 days agoWhy Exelixis Stock Fell Last Week
On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.
- Benzinga•5 days ago
Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...
- Business Wire•5 days ago
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis, Inc. today announced that its partner Ipsen received approval from the European Commission for CABOMETYX® 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma in the European Union.
- Zacks•6 days ago
Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?
Investors in Exelixis (EXEL) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•11 days ago
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
- Market Realist•11 days ago
Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018
On March 7, Merck (MRK) announced that it had entered a collaboration with Eisai for the co-development and co-commercialization of the latter’s oral protein tyrosine kinase inhibitor, Lenvima, as a monotherapy and in combination regimens with Keytruda in multiple oncology indications. Lenvima monotherapy is currently approved in more than 50 countries as treatment for progressive differentiated thyroid cancer patients that witness disease progression despite being treated with radioactive iodine therapy. Lenvima in combination with Novartis’s (NVS) Afinitor is approved in more than 40 countries for the second-line renal cell carcinoma indication.
- Zacks•11 days ago
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
- Zacks•11 days ago
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher
Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
- Zacks•11 days ago
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
- Motley Fool•11 days ago
3 Healthcare Stocks Growing Over 100%
Massive sales growth at these companies could make them the perfect stocks to add to your portfolio.
- Investor's Business Daily•12 days ago
This Biotech Stock Crashed On Colon Cancer Flop With Roche
Exelixis stock tanked Thursday after a regimen using its drug and another from Roche failed in a late-stage study of hard-to-treat colon cancer patients.
- Motley Fool•12 days ago
Why Booking Holdings, Exelixis, and L Brands Slumped Today
Find out how earnings hurt some of these companies despite a strong market day.
- Zacks•12 days ago
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.
- Motley Fool•12 days ago
Why Exelixis Dropped Today
The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.
- Zacks•12 days ago
5 Winning Stocks With Superb Efficiency Level
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Market Realist•12 days agoAnalysts’ Recommendations for Regeneron Pharmaceuticals in May
In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.
